Avoid testosterone in PCa patients, experts advise
Paris-The International Consultation on Prostate Cancer recommends thatmen with a history of prostate cancer not be given testosterone supplementationunder any circumstance. The recommendation was the subject of lively debateat the consultation's 2002 meeting here, and some members of the audienceposed cases in which they thought hormone replacement might be appropriate.
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.